Catabasis Pharmaceuticls’ (CATB) “Outperform” Rating Reaffirmed at Wedbush
Wedbush reiterated their outperform rating on shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) in a research note published on Thursday. Wedbush currently has a $17.00 price objective on the stock.
Separately, Zacks Investment Research cut shares of Catabasis Pharmaceuticls from a buy rating to a hold rating in a research note on Monday, July 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Catabasis Pharmaceuticls presently has an average rating of Buy and an average price target of $19.05.
Shares of Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 1.0329% on Thursday, reaching $4.9102. 8,304 shares of the company were exchanged. The stock’s market capitalization is $75.52 million. The firm has a 50 day moving average price of $4.77 and a 200-day moving average price of $4.74. Catabasis Pharmaceuticls has a 12-month low of $3.31 and a 12-month high of $10.83.
Catabasis Pharmaceuticls (NASDAQ:CATB) last released its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.04. On average, analysts predict that Catabasis Pharmaceuticls will post ($2.47) EPS for the current fiscal year.
A hedge fund recently raised its stake in Catabasis Pharmaceuticls stock. Sphera Funds Management LTD. increased its position in Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) by 184.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 230,041 shares of the company’s stock after buying an additional 149,299 shares during the period. Sphera Funds Management LTD. owned approximately 1.50% of Catabasis Pharmaceuticls worth $1,159,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 57.27% of the company’s stock.
About Catabasis Pharmaceuticls
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Stock Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related stocks with our FREE daily email newsletter.